Subscribe free!

Find out why we're the #1 free penny stock alert newsletter


Small-Cap Stock in News: Vical Inc. (VICL)

| |

Shares of Vical Inc. (NASDAQ: VICL), a biotechnology company engaged in research and development of biopharmaceutical products based in DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, are soaring in today’s trading.

At last check, the small-cap stock of VICL was trading 6.10% higher at $4, with volume up from daily average of 325,148 to 2.98 million. The stock touched an intra-day high of $4.24 in today’s trading. Year-to-date, the stock has fallen 9.75%.

VICL shares are gaining after the company today announced that it granted a worldwide, nonexclusive license to Bristol-Myers Squibb Company (NYSE: BMY) of its patented platform DNA immunization technology and its Vaxfectin® adjuvant for use in the production of antibodies.

As per the terms of the agreement, BMY will use VICL’s technology to generate antibodies with potential therapeutic uses in humans. Under the agreement, the company will also provide specific quantities of the Vaxfectin adjuvant to BMY from time to time. VICL did not disclose the financial terms of the agreement with BMY.

Commenting on the agreement, Vijay B. Samant, president and CEO of Vical, said that VICL is pleased to enter into the agreement with BMY. Samant noted that the agreement recognizes an important application of VICL’s DNA immunization technology. He further said that DNA immunization has been used widely in research setting as an efficient means of antibody production and the agreement represents a meaningful step toward monetizing a common use of VICL’s broadly applicable intellectual property asset.

The agreement also establishes a template for additional agreements with others working in the field, according to Samant. He added that VICL’s Vaxfectin adjuvant has shown significant improvement in the efficiency of the immunization process and the company is excited to establish the initial license agreement for Vaxfectin as well.

Posted by on Thursday, September 13th, 2012. Filed under Internet, Technology. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of BlueWave Advisors.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Leave a Reply